MCID: ARG006
MIFTS: 28

Aregenerative Anemia

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Aregenerative Anemia

MalaCards integrated aliases for Aregenerative Anemia:

Name: Aregenerative Anemia 58 70
Refractory Anemias 70

Classifications:

Orphanet: 58  
Rare haematological diseases


Summaries for Aregenerative Anemia

MalaCards based summary : Aregenerative Anemia, also known as refractory anemias, is related to diamond-blackfan anemia 1 and diamond-blackfan anemia. An important gene associated with Aregenerative Anemia is TBXAS1 (Thromboxane A Synthase 1). The drugs Cytarabine and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and bone, and related phenotypes are pallor and bone marrow hypocellularity

Related Diseases for Aregenerative Anemia

Diseases related to Aregenerative Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 diamond-blackfan anemia 1 11.3
2 diamond-blackfan anemia 11.2
3 ghosal hematodiaphyseal dysplasia 11.1
4 deficiency anemia 10.5
5 thymoma, familial 10.4
6 thymoma 10.4
7 pancytopenia 10.0
8 glucosephosphate dehydrogenase deficiency 10.0
9 monocytic leukemia 10.0
10 refractory anemia 10.0

Graphical network of the top 20 diseases related to Aregenerative Anemia:



Diseases related to Aregenerative Anemia

Symptoms & Phenotypes for Aregenerative Anemia

Human phenotypes related to Aregenerative Anemia:

58 31 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pallor 58 31 hallmark (90%) Very frequent (99-80%) HP:0000980
2 bone marrow hypocellularity 58 31 hallmark (90%) Very frequent (99-80%) HP:0005528
3 reticulocytopenia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001896
4 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
5 dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002094
6 depressivity 58 31 occasional (7.5%) Occasional (29-5%) HP:0000716
7 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
8 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
9 neutropenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001875
10 bruising susceptibility 58 31 occasional (7.5%) Occasional (29-5%) HP:0000978
11 pancytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001876
12 mood changes 58 31 occasional (7.5%) Occasional (29-5%) HP:0001575
13 fatigable weakness of skeletal muscles 58 31 occasional (7.5%) Occasional (29-5%) HP:0030197
14 erythroid hypoplasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0012133
15 abnormality of interleukin secretion 58 31 occasional (7.5%) Occasional (29-5%) HP:0011117
16 decreased proportion of cd4-positive helper t cells 31 occasional (7.5%) HP:0005407
17 abnormal proportion of cd8-positive t cells 31 occasional (7.5%) HP:0031393
18 lymphadenopathy 58 31 very rare (1%) Very rare (<4-1%) HP:0002716
19 dementia 58 31 very rare (1%) Very rare (<4-1%) HP:0000726
20 cognitive impairment 58 Very rare (<4-1%)
21 abnormality of the cardiovascular system 58 Occasional (29-5%)
22 abnormality of immune system physiology 58 Occasional (29-5%)
23 abnormal bleeding 58 Occasional (29-5%)
24 abnormality of bone marrow cell morphology 58 Frequent (79-30%)
25 decreased proportion of cd4-positive t cells 58 Occasional (29-5%)
26 abnormal proportion of cd8 t cells 58 Occasional (29-5%)

Drugs & Therapeutics for Aregenerative Anemia

Drugs for Aregenerative Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
2
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Daunorubicin Approved Phase 3 20830-81-3 30323
5
Idarubicin Approved Phase 3 58957-92-9 42890
6
Molgramostim Investigational Phase 3 99283-10-0
7 Antineoplastic Agents, Immunological Phase 3
8 Antimetabolites Phase 3
9 Anti-Infective Agents Phase 3
10 Immunologic Factors Phase 3
11 Adjuvants, Immunologic Phase 3
12 Immunosuppressive Agents Phase 3
13 Antiviral Agents Phase 3
14 Gemtuzumab Phase 3
15 Antibiotics, Antitubercular Phase 3
16 Anti-Bacterial Agents Phase 3
17
Panitumumab Approved, Investigational Phase 1 339177-26-3 50070211
18
Decitabine Approved, Investigational Phase 1 2353-33-5 451668
19
Irinotecan Approved, Investigational Phase 1 100286-90-6, 97682-44-5 60838
20
Oxaliplatin Approved, Investigational Phase 1 61825-94-3 5310940 9887054 43805 6857599
21
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
22
Alvocidib Experimental, Investigational Phase 1 146426-40-6, 131740-09-5 5287969
23 Antibodies Phase 1
24 Mitogens Phase 1
25 Cola Phase 1
26 Immunoglobulins Phase 1
27 Antibodies, Monoclonal Phase 1
28 Histone Deacetylase Inhibitors Phase 1
29 Protein Kinase Inhibitors Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
2 Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
3 A Randomized Multicenter Study of More Intensive Versus Less Intensive Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia (AML) or Transformed Refractory Anemia With Excess Blasts (RAEB-t). Terminated NCT00363025 Phase 3 Idarubicin versus daunorubicin
4 Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated With Severe Neutropenia Refractory to Immunosuppressive Therapy Active, not recruiting NCT00604201 Phase 2
5 Targeted Demethylation to Enhance Response or Overcome Resistance to EGFR Blocking Agents in KRAS Wild-type Metastatic Colorectal Cancer Patients Using Sequential Decitabine and Panitumumab Completed NCT00879385 Phase 1 Dacogen™ (decitabine);Vectibix® (panitumumab)
6 Phase I Trial of Vorinostat (SAHA) in Combination With Alvocidib (Flavopiridol) in Patients With Relapsed, Refractory, or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia With Excess Blasts-2 Completed NCT00278330 Phase 1 alvocidib;vorinostat

Search NIH Clinical Center for Aregenerative Anemia

Genetic Tests for Aregenerative Anemia

Anatomical Context for Aregenerative Anemia

MalaCards organs/tissues related to Aregenerative Anemia:

40
Bone Marrow, T Cells, Bone, Thymus, Myeloid, Neutrophil

Publications for Aregenerative Anemia

Articles related to Aregenerative Anemia:

(show top 50) (show all 156)
# Title Authors PMID Year
1
[Erythrophagocytosis by blast cells and de novo T cell LAL without cytogenetic abnormalities in a Moroccan patient]. 61
32963668 2020
2
Intrauterine Growth Retardation Complicated by Biermer's Disease: An Observation in Togo. 61
31198611 2019
3
TREATMENT STRATEGIES AND OUTCOME OF PARVOVIRUS B19 INFECTION IN KIDNEY TRANSPLANT RECIPIENTS: A CASE SERIES AND LITERATURE REVIEW OF 128 PATIENTS. 61
31448778 2019
4
Citrobacter freundii infection in silver catfish (Rhamdia quelen): Hematological and histological alterations. 61
30266258 2018
5
Hospital-Based Case-Control Study of MDS Subtypes and Benzene Exposure in Shanghai. 61
28146040 2017
6
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. 61
27562492 2016
7
Adult-onset Diamond-Blackfan anemia with a novel mutation in the exon 5 of RPL11: too late and too rare. 61
26185635 2015
8
Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. 61
26124688 2015
9
Immune aregenerative anemia without erythroblastopenia: a previously undescribed condition. 61
23408098 2013
10
[Refractory anemias]. 61
24195247 2013
11
Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. 61
23065512 2013
12
[Detecting a peak in fraction beta by capillary electrophoresis: interference due to iomeprol]. 61
23587586 2013
13
How I treat transfusional iron overload. 61
22919029 2012
14
[Aregenerative anemia and erythrocytes hemighosts: a case report]. 61
21896417 2011
15
[Criteria for suspecting a myelodysplastic syndrome]. 61
21425539 2010
16
Genetic variants in the noncoding region of RPS19 gene in Diamond-Blackfan anemia: potential implications for phenotypic heterogeneity. 61
20054847 2010
17
[Neonatal Pearson syndrome. two case studies]. 61
19914050 2010
18
Nandrolone decanoate for the treatment of erythropoietin refractory anemia: a case series. 61
20043618 2009
19
[Pernicious anemia in an adolescent with type 1 diabetes mellitus]. 61
19211232 2009
20
Early neurological impairment and severe anemia in a newborn with Pearson syndrome. 61
18553104 2009
21
Treatment of iron overload in thalassemia. 61
19337180 2008
22
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 61
18497321 2008
23
Treatment options in myelodysplastic syndromes: a new frontier. 61
18606581 2008
24
[Immune pathophysiology of refractory anemias]. 61
18326316 2008
25
Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. 61
18037415 2007
26
Linezolid-related pancytopenia in organ-transplant patients: report of two cases. 61
17653505 2007
27
Unusual complex hyperdiploid karyotypes in myelodysplastic syndromes. 61
17011983 2006
28
Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. 61
16314788 2005
29
Absence of p16 and p27 gene rearrangements and mutations in de novo myelodysplastic syndromes. 61
16104874 2005
30
A comparative review of classification systems in myelodysplastic syndromes (MDS). 61
16085011 2005
31
[Extensive bone marrow necrosis as presenting manifestation of sickle cell disease in Africa]. 61
15460150 2004
32
Increased caspase-3 activity in refractory anemias: lack of evidence for Fas pathway implication. 61
12399987 2002
33
Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia. 61
12163050 2002
34
[Transient erythroblastopenia in the context of Epstein-Barr virus infection]. 61
12042121 2002
35
Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. 61
11858190 2002
36
Lethal hydrops fetalis due to congenital dyserythropoietic anemia in a newborn: association of a new skeletal abnormality. 61
11764104 2001
37
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. 61
11493439 2001
38
Diamond-Blackfan anemia. 61
11176237 2001
39
Secondary iron overload. 61
11722978 2001
40
[Collagen gastritis, an unusual cause of anemia in children. Report of 2 cases]. 61
11218583 2001
41
Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry. 61
10654453 2000
42
Nutritional anemias. 61
10595751 1999
43
Rheumatoid arthritis associated with myelodysplastic syndrome: a case report. 61
10402176 1999
44
EPR spin trapping and 2-deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on *OH formation by the Fenton reaction. 61
10076064 1999
45
CD66c antigen expression is myeloid restricted in normal bone marrow but is a common feature of CD10+ early-B-cell malignancies. 61
9714468 1998
46
Transfusion-associated iron overload. 61
9359002 1997
47
Myelodysplasia and the leukemias. 61
9301644 1997
48
Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16, p18 and p19 in the myelodysplastic syndromes. 61
9111168 1997
49
Iron chelation therapy. 61
9371986 1995
50
Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients. 61
7813708 1994

Variations for Aregenerative Anemia

Expression for Aregenerative Anemia

Search GEO for disease gene expression data for Aregenerative Anemia.

Pathways for Aregenerative Anemia

GO Terms for Aregenerative Anemia

Sources for Aregenerative Anemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....